Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

40.25
+2.757.33%
Post-market: 39.05-1.2000-2.98%19:59 EDT
Volume:4.59M
Turnover:190.47M
Market Cap:4.77B
PE:-7.65
High:43.69
Open:42.01
Low:40.16
Close:37.50
Loading ...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Dec 2024

FDA Accepts Cytokinetics' Application for Cardiovascular Drug

Zacks
·
04 Dec 2024

Cytokinetics Begins Phase 3 Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure

MT Newswires Live
·
04 Dec 2024

Cytokinetics opens enrollment for COMET-HF Phase 3 trial

TIPRANKS
·
03 Dec 2024

Cytokinetics Announces Start of Comet-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction

THOMSON REUTERS
·
03 Dec 2024

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)

TIPRANKS
·
03 Dec 2024

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
02 Dec 2024

Cytokinetics Shares Down 1.2% After FDA Grants Standard Review for Co's Heart Disease Drug

THOMSON REUTERS
·
02 Dec 2024

BUZZ-Cytokinetics falls on standard review for heart disease drug

Reuters
·
02 Dec 2024

Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy

MT Newswires Live
·
02 Dec 2024

BRIEF-Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Reuters
·
02 Dec 2024

Cytokinetics Inc - Pdufa Target Action Date Set for September 26, 2025

THOMSON REUTERS
·
02 Dec 2024

Cytokinetics Inc - FDA Not Planning Advisory Committee Meeting for Aficamten Nda

THOMSON REUTERS
·
02 Dec 2024

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
02 Dec 2024

RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
28 Nov 2024

FDA Accepts Bayer's Application for Label Expansion of Nubeqa

Zacks
·
23 Nov 2024

Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?

Insider Monkey
·
22 Nov 2024

Cytokinetics price target raised to $103 from $99 at Mizuho

TIPRANKS
·
21 Nov 2024

Cytokinetics Secures Strategic Partnership with Bayer: Analyst Recommends Buy Rating

TIPRANKS
·
21 Nov 2024

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

Zacks
·
20 Nov 2024